Non-alcoholic fatty liver disease (NAFLD), one of the most common liver diseases, is caused by the disruption of hepatic lipid homeostasis. It is associated with insulin resistance as seen in type 2 diabetes mellitus. Glucagon-like peptide-1 (GLP-1) is an incretin that increases insulin sensitivity and aids glucose metabolism. In recent in vivo and in vitro studies, GLP-1 presents a novel therapeutic approach against NAFLD by increasing fatty acid oxidation, decreasing lipogenesis, and improving hepatic glucose metabolism. In this report, we provide an overview of the role and mechanism of GLP-1 in relieving NAFLD
The only known, effective intervention for non-alcoholic fatty liver disease (NAFLD) is weight loss,...
1 Summary GLP-1 (glucagon-like peptide-1) is a peptide hormone belonging to the group of incretins t...
Nonalcoholic fatty liver disease (NAFLD) is a serious form of chronic liver disease that is characte...
Non-alcoholic fatty liver disease (NAFLD) is a main cause of liver disease and its global prevalence...
IF 4.101International audienceNon-alcoholic fatty liver disease (NAFLD) is very common in patients w...
Glucagon-like peptide-1 (GLP-1)-based therapies have demonstrated efficacy and safety in treating ty...
To date, non-alcoholic fatty liver disease (NAFLD) is the most frequent liver disease, affecting up ...
The incretins glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP)...
Glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) are incretins...
The incretins glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP)...
Background & Aims: The incretins glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinot...
High-fat dietary intake and low physical activity lead to insulin resistance, nonalcoholic fatty liv...
Background/Aims: High-fat dietary intake and low physical activity lead to insulin resistance, nonal...
Nonalcoholic fatty liver disease (NAFLD) is the leading cause of liver disease worldwide, and no eff...
Incretin-based therapies have shown promise in the treatment of type 2 diabetes. Here we review our ...
The only known, effective intervention for non-alcoholic fatty liver disease (NAFLD) is weight loss,...
1 Summary GLP-1 (glucagon-like peptide-1) is a peptide hormone belonging to the group of incretins t...
Nonalcoholic fatty liver disease (NAFLD) is a serious form of chronic liver disease that is characte...
Non-alcoholic fatty liver disease (NAFLD) is a main cause of liver disease and its global prevalence...
IF 4.101International audienceNon-alcoholic fatty liver disease (NAFLD) is very common in patients w...
Glucagon-like peptide-1 (GLP-1)-based therapies have demonstrated efficacy and safety in treating ty...
To date, non-alcoholic fatty liver disease (NAFLD) is the most frequent liver disease, affecting up ...
The incretins glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP)...
Glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) are incretins...
The incretins glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP)...
Background & Aims: The incretins glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinot...
High-fat dietary intake and low physical activity lead to insulin resistance, nonalcoholic fatty liv...
Background/Aims: High-fat dietary intake and low physical activity lead to insulin resistance, nonal...
Nonalcoholic fatty liver disease (NAFLD) is the leading cause of liver disease worldwide, and no eff...
Incretin-based therapies have shown promise in the treatment of type 2 diabetes. Here we review our ...
The only known, effective intervention for non-alcoholic fatty liver disease (NAFLD) is weight loss,...
1 Summary GLP-1 (glucagon-like peptide-1) is a peptide hormone belonging to the group of incretins t...
Nonalcoholic fatty liver disease (NAFLD) is a serious form of chronic liver disease that is characte...